Histone modification marker combination for sepsis and application and kit thereof

By detecting the histone H3K18 la/ac ratio, the problem of low diagnostic accuracy and susceptibility to early intervention in existing technologies for sepsis has been solved, achieving highly sensitive and specific sepsis assessment and prognostic prediction.

CN120275641BActive Publication Date: 2025-11-28BEIJING HOSPITAL
1 Cites 0 Cited by

Patent Information

Application Number
CN202510300082.X
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2025-03-13
Publication Date
2025-11-28
Estimated Expiration
2045-03-13

AI Technical Summary

Technical Problem

Current technologies for the diagnosis of sepsis have low diagnostic accuracy, are easily affected by early clinical interventions, have difficulty in early identification of severe cases of infection and non-infection, and lack sensitive and specific biomarkers.

Method used

The ratio of lactation modification level (H3K18la) to acetylation modification level (H3K18ac) of histone H3 lysine residue 18 (H3K18la/ac) was used as a biomarker. Western blot detection and data analysis were used to distinguish between severe infection and non-severe infection, assess the severity of sepsis and prognosis.

Benefits of technology

It provides a highly sensitive and specific combination of biomarkers that can accurately distinguish between severe infectious and non-infectious cases, assess the severity of sepsis, predict prognosis, and reduce the impact of early clinical intervention.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The application provides a histone modification marker combination for sepsis and application and kit thereof, and belongs to the field of biomarkers. Through obtaining peripheral blood mononuclear cells, histone extraction, Western blot detection and data analysis, it is proved that the ratio (H3K18la / ac) of the acetylation modification level (H3K18ac) and the lysine residue lactylation modification level (H3K18la) of the 18th lysine residue of histone H3 can be used as a sepsis evaluation marker, and the kit can be used for distinguishing sepsis infection severe cases from non-infection severe cases, sepsis severity evaluation and sepsis prognosis prediction.
Need to check novelty before this filing date? Find Prior Art